Welcome to our dedicated news page for Spruce Biosciences (Ticker: SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Spruce Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Spruce Biosciences's position in the market.
Rhea-AI Summary
Spruce Biosciences (Nasdaq: SPRB) is set to present baseline characteristics of its CAHmelia program at the Pediatric Endocrine Society 2024 Annual Meeting, highlighting tildacerfont in adult congenital adrenal hyperplasia management. The presentation aims to address unmet medical needs in pediatric CAH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
-
Rhea-AI Summary
Spruce Biosciences, Inc. (SPRB) reports financial results for 2023, highlighting positive data from CAHptain-205 study in pediatric classic CAH and challenges faced in CAHmelia-203 study for adult classic CAH. The company plans to meet regulatory authorities in 2025 for a registrational clinical program. Cost reductions extend cash runway through 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-84.38%
Tags
-
Rhea-AI Summary
Spruce Biosciences, Inc. (Nasdaq: SPRB) announced topline results from its CAHmelia-203 and CAHptain-205 studies of tildacerfont in adult and pediatric classic congenital adrenal hyperplasia (CAH). While CAHmelia-203 did not meet its primary efficacy endpoint, CAHptain-205 showed promising results. The company plans to meet regulatory authorities for a potential registrational program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-84.38%
Tags
News
Rhea-AI Summary
Spruce Biosciences, Inc. (SPRB) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The CEO will discuss the development and commercialization of novel therapies for rare endocrine disorders. The live webcast can be accessed on the company's investor relations website, with an archived copy available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.71%
Tags
-
Rhea-AI Summary
Spruce Biosciences, Inc. (Nasdaq: SPRB) has completed enrollment in its CAHmelia-204 clinical trial of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH), enrolling 100 patients, exceeding the target of 90. The company anticipates reporting topline results in the third quarter of 2024, with plans to meet with regulatory authorities to discuss the potential registrational path forward for tildacerfont. CAHmelia-204 is a randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of tildacerfont in reducing glucocorticoid usage in adults with classic CAH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
-
Rhea-AI Summary
Spruce Biosciences, Inc. (SPRB) reported baseline characteristics of patients enrolled in the CAHmelia-203 and CAHmelia-204 clinical studies of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH). The company's CEO, Javier Szwarcberg, highlighted the significance of hyperandrogenemia and hypercortisolemia within this patient population. Patients in CAHmelia-203 enrolled with mean baseline A4 levels nearly six times above the upper limit of normal on a mean baseline daily glucocorticoid (GC) dose of 27 mg hydrocortisone equivalents (HCe). On the other hand, patients in CAHmelia-204 enrolled with a mean baseline daily GC dose of 35 mg HCe and suppressed levels of A4. Spruce Biosciences looks forward to reporting topline results from CAHmelia-203 in March, followed by CAHmelia-204 in the third quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
Rhea-AI Summary
Spruce Biosciences, a late-stage biopharmaceutical company (Nasdaq: SPRB), is making significant progress in developing novel therapies for rare endocrine disorders, with upcoming milestones including topline results from CAHmelia-203 and CAHptain-205 in March 2024, and from CAHmelia-204 in Q3 2024. The company also anticipates maintaining cash runway into the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
-
Rhea-AI Summary
Spruce Biosciences, Inc. (Nasdaq: SPRB) reported financial results for Q3 2023, highlighted by the completion of enrollment in the CAHptain-205 and CAHmelia-203 studies for rare endocrine disorders. The company also provided updates on upcoming milestones and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
-
Rhea-AI Summary
Spruce Biosciences, Inc. (Nasdaq: SPRB) will participate in the Jefferies London Healthcare Conference on November 14-16, 2023. Archived webcasts from investor conferences are available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
Rhea-AI Summary
Spruce Biosciences has announced the completion of target enrollment in the CAHmelia-203 clinical trial for the treatment of adult classic congenital adrenal hyperplasia (CAH). The company has enrolled 72 patients and closed screening in the trial. Final enrollment is expected to exceed the original target due to substantial patient interest. The topline results from this study, along with the results from all cohorts in the CAHptain clinical trial, are anticipated in the first quarter of 2024. Spruce Biosciences also provided updated anticipated milestones for other ongoing trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.97%
Tags
Spruce Biosciences Inc
Nasdaq:SPRB
SPRB Rankings
SPRB Stock Data
30.30M
13.54M
7.75%
71.24%
0.78%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States
South San Francisco
About SPRB
spruce biosciences is a clinical stage biopharmaceutical company focused on developing novel therapies for rare diseases affecting the endocrine system.